Ozempic’s Success Is Bad News for Rivals

Featuring some of our favorite conversations of the week from our daily radio show "Bloomberg Businessweek Daily." Hosted by Carol Massar and Tim Stenovec Hear the show live at 2PM ET on WBBR 1130 AM New York, Bloomberg 92.9 FM Boston, WDCH 99.1 FM in Washington D.C. Metro, Siriu ... Show More

Watch Bloomberg Businessweek Daily every day on YouTube: http://bit.ly/3vTiACF.President Donald Trump threatened a 35% tariff on some Canadian goods and raised the prospect of increasing levies on most other countries, ramping up his trade rhetoric in comments that weighed on sto ... Show More

Ramaco Resources, Inc. and Ramaco Rare Earth, LLC are hosting a landmark ribbon cutting and groundbreaking ceremony on Friday, July 11, to commemorate the opening of the Brook Mine Carbon Ore Rare Earth project. It will be the first new rare earth mine in the United States in mor ... Show More

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More

Bloomberg BNA's Eleanor Tyler joins Tom Keene and Mike McKee to discuss pharmaceutical mergeres, tax inversions, drug pricing, and the renewed efforts by the Federal Trade Commission to regulate an increasingly complicated industry. Learn more about your ad-choices at https://www ... Show More

Moderna CEO Stephane Bancel talks about the Moderna vaccine, drug prices, and future of the company with Bloomberg's Paul Sweeny and Matt Miller. See omnystudio.com/listener for privacy information. 

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ... Show More

As a number of existing therapies are being re-purposed to help patients with the most severe Covid-19 symptoms, we speak to a UK-based bioscience company about a drug they've developed and explore how it is being used in Italy.  Guests: Tom Whipple, The Times science editorSomei ... Show More

In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry. How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 10,000 time ... Show More

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ... Show More